271. 強直性脊椎炎 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019872-65-GB   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
0881   
   Wyeth Farma S.A.
      2006   -   EUCTR2006-002349-35-ES   Spain;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
146368   
   Celgene Corporation
      2021   Phase 2   EUCTR2019-004108-37-DE   Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
18F]Fluoride   
   VU Medical Center, department of Rheumatology
      2018   Phase 4   EUCTR2017-004850-40-NL   Netherlands;
331731-18-1   
   Abbott
      -   -   EUCTR2014-004532-18-Outside-EU/EEA   Japan;
42942019   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019872-65-GB   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
5057732   
   AMC
      2014   -   EUCTR2013-002860-19-NL   Netherlands;
99mTc-rhAnnexin V-128   
   Advanced Accelerator Applications
      2014   Phase 1/Phase 2   NCT02328027   Switzerland;
ABT-494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-003229-12-IT   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2019-003229-12-SK   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003229-12-HU   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003229-12-GB   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003229-12-ES   Argentina;Australia;Brazil;Canada;China;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003229-12-DE   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-SE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-NL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-HR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-DE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-HU   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-GB   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FI   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-ES   Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-DK   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-CZ   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-BE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
ABY-035   
   Inmagene Biopharmaceuticals
      2021   Phase 2   NCT04795141   Cayman Islands;
AIN457   
   NOVARTIS FARMA
      2011   -   EUCTR2010-024529-18-IT   Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2013-005575-41-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;United Kingdom;
   Novartis Farma SpA
      2013   Phase 3   EUCTR2013-001089-40-IT   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2015   Phase 3   EUCTR2013-005575-41-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001090-24-ES   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000046-35-ES   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
      2020   Phase 3   EUCTR2019-001177-90-SE   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      2020   Phase 3   EUCTR2019-001177-90-IT   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      2020   Phase 3   EUCTR2019-001177-90-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      2020   Phase 3   EUCTR2019-001177-90-CZ   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      2020   Phase 3   EUCTR2019-001177-90-BG   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
      -   Phase 4   EUCTR2020-004284-98-CZ   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany;
   Novartis Pharma K.K.
      2016   Phase 3   JPRN-JapicCTI-163241   -
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005021-39-GB   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
      2016   Phase 3   EUCTR2015-005021-39-CZ   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
      2015   Phase 3   EUCTR2013-005575-41-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-NO   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-FI   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-DK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005575-41-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-PT   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-NO   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-GR   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-GB   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-DE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001090-24-BE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001090-24-CZ   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000046-35-NL   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000046-35-GB   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000046-35-FI   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000046-35-DE   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011591-30-GB   Germany;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011591-30-NL   Germany;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011591-30-DE   Germany;Netherlands;United Kingdom;
      2009   -   EUCTR2008-002631-33-NL   Germany;Netherlands;United Kingdom;
      2009   -   EUCTR2008-002631-33-GB   Germany;Netherlands;United Kingdom;
      2008   -   EUCTR2008-002631-33-DE   Germany;Netherlands;United Kingdom;
   Novartis Pharmaceuticals
      2009   Phase 2   NCT00809159   Germany;Netherlands;United Kingdom;United States;
AIN457,   
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
AIN457A   
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01109940   Germany;Netherlands;United Kingdom;United States;
AIN457F   
   NOVARTIS FARMA
      2012   Phase 3   EUCTR2012-000046-35-IT   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
ARCOXIA 90 mg comprimidos recubiertos con película   
   FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
      2010   -   EUCTR2009-017309-12-ES   Spain;
ARRY-371797   
   Array BioPharma Inc.
      2009   -   EUCTR2008-007510-30-PL   Hungary;Poland;
      2009   -   EUCTR2008-007510-30-HU   Hungary;Poland;
ARRY-371797, p38 inhibitor   
   Pfizer
      2008   Phase 2   NCT00811499   Canada;United States;
AS   
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2009   -   ChiCTR-ONRC-11001565   -
   Department of rheumatology of the Chinese PLA General Hospital
      2015   -   ChiCTR-IPR-15006753   China;
   Guangdong Provincial Hospital of Chinese Medicine
      2007   Phase 1 study   ChiCTR-TRC-13004564   China;
   PLA General Hospital
      2018   -   ChiCTR1800019227   China;
   The First Affiliated Hospital of Suzhou University
      2021   Phase 0   ChiCTR2100044377   China;
Abatacept   
   Charite University, Berlin, Germany
      2008   Phase 2   NCT00558506   Germany;
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany;
Aclasta   
   Cambridge University Hospitals NHS Foundation Trust
      2007   -   EUCTR2007-000087-25-GB   United Kingdom;
Adalimumab   
   ABBOTT
      2006   -   EUCTR2005-004826-21-IT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
   AbbVie
      2016   -   NCT02750800   Hungary;
      2014   -   NCT02333383   Korea, Republic of;
      2013   -   NCT01768858   Austria;
   Abbott
      2010   Phase 3   NCT01114880   China;
      2008   Phase 3   NCT00667355   Japan;
   Abbott GmbH & Co. KG
      2007   -   EUCTR2005-004826-21-BE   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004826-21-DK   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-SE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-IE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-GR   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-GB   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-FI   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-ES   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-DE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-AT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
   Abbott Japan Co., Ltd.
      2008   Phase 3   JPRN-JapicCTI-080580   -
   Abbott Laboratories
      2006   -   EUCTR2005-004826-21-NO   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
   Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
      2008   -   EUCTR2007-003358-27-DE   Germany;
   Chung Shan Medical University
      2008   Phase 4   NCT02489760   Taiwan;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
      2014   Phase 3   NCT01870284   Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Innovent Biologics (Suzhou) Co. Ltd.
      2016   Phase 3   NCT02893254   -
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Mianyang Hospital of Traditional Chinese Medicine
      2021   Phase 4   ChiCTR2100044045   China;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Regionshospitalet Silkeborg
      2010   Phase 4   NCT01174186   Denmark;
   Universidade Nova de Lisboa
      2015   Phase 4   NCT02492217   Portugal;
   University Hospital, Tours
      2013   Phase 4   NCT01895764   France;
Adalimumab (D2E7)   
   Abbott
      2004   Phase 3   NCT00085644   United States;
      2003   Phase 3   NCT00195819   Canada;United States;
Adalimumab (Humira)   
   Abbott
      2006   Phase 3   NCT00478660   Austria;Belgium;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
Adalimumab 40 mg sc every other week   
   Charite University, Berlin, Germany
      2005   Phase 2/Phase 3   NCT00235105   Germany;
Adalimumab and its biosimilars   
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Adalimumab, Etanercept, Golimumab or infliximab   
   University Hospital, Montpellier
      2012   -   NCT01610947   France;
Alendronate   
   Göteborg University
      2009   -   NCT01104987   Sweden;
Anti TNF alpha agent   
   All India Institute of Medical Sciences, New Delhi
      2011   -   NCT01361542   India;
Anti TNF alpha therapy   
   All India Institute of Medical Sciences, New Delhi
      2011   -   NCT01361542   India;
Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)   
   Rheumazentrum Ruhrgebiet.
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom;
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom;
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom;
Anti-Human Interleukin-23 Monoclonal Antibody   
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Anti-TNF   
   University Hospital, Bordeaux
      2015   Phase 3   NCT02469753   France;Monaco;
Anti-TNF agents   
   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
      2019   -   NCT04943237   Turkey;
Anti-TNF therapy (etanercept or adalimumab)   
   Imperial College London
      2010   -   NCT01060098   United Kingdom;
Anti-Tumor Necrosis Factor   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1999   Phase 2   NCT00000433   United States;
Apremilast   
   Celgene Corporation
      2013   Phase 3   EUCTR2011-001555-37-EE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-SE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
   Imperial College London
      2009   Phase 2   NCT00944658   United Kingdom;
      2009   -   EUCTR2008-004229-40-GB   United Kingdom;
Apremilast tablet 30 mg BID   
   Amgen
      2012   Phase 3   NCT01583374   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
BAT1406   
   Bio-Thera Solutions
      2016   Phase 3   NCT04135508   -
BCD-055   
   Biocad
      2016   Phase 3   NCT02762812   Russian Federation;
BCD-085   
   Biocad
      2018   Phase 3   NCT03447704   Russian Federation;
      2016   Phase 2   NCT02763111   -
BDMARD treatment   
   Uppsala University
      2005   -   NCT02840695   -
BI 655066 90 mg/ml   
   Boehringer Ingelheim
      2014   Phase 2   EUCTR2013-003666-13-IT   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
   Boehringer Ingelheim España, S.A.
      2013   Phase 2   EUCTR2013-003666-13-ES   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
   Boehringer Ingelheim Finland Ky
      2013   Phase 2   EUCTR2013-003666-13-FI   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2014   Phase 2   EUCTR2013-003666-13-DE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
   Boehringer-Ingelheim bv
      2014   Phase 2   EUCTR2013-003666-13-NL   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
   SCS Boehringer Ingelheim Comm.V
      2014   Phase 2   EUCTR2013-003666-13-BE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
BI 730357   
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2019-001684-77-HU   Belgium;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Moldova, Republic of;Romania;Spain;Ukraine;United States;
BMS-188667   
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany;
BMS-986251   
   Bristol-Myers Squibb
      2017   Phase 1/Phase 2   NCT03329885   Netherlands;
Bawei Shenqi Pill   
   Shanghai University of Traditional Chinese Medicine
      2017   Phase 2/Phase 3   NCT04480359   China;
Bimekizumab   
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03215277   Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2016   Phase 2   NCT02963506   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2016-001102-42-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001102-42-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2016-001102-42-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001102-42-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001102-42-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001102-42-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   UCB Biopharma SRL
      2020   Phase 3   NCT04436640   Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   NCT03928743   Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2017   Phase 2   NCT03355573   Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
   UCB Japan Co., Ltd
      2019   Phase 3   JPRN-JapicCTI-194860   Japan, Asia except Japan, North America;
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205414   Japan, Asia except Japan, North America, Europe;
Biologic DMARD   
   Seoul National University Hospital
      2013   -   NCT01965132   Korea, Republic of;
Biosimilar   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia;
Blood collection   
   CHU de Reims
      2015   -   NCT02809300   France;
Blood samples   
   Assistance Publique Hopitaux De Marseille
      2017   -   NCT03322618   France;
Blood sampling from infant   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from mother   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Breast milk sampling   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States;
CC-10004   
   Celgene Corporation
      2013   Phase 3   EUCTR2011-001555-37-EE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-SE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001555-37-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
   Imperial College London
      2009   -   EUCTR2008-004229-40-GB   United Kingdom;
CC-99677   
   Celgene
      2021   Phase 2   NCT04947579   Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 30mg Capsule   
   Celgene Corporation
      2021   Phase 2   EUCTR2019-004108-37-DE   Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 60mg Capsule   
   Celgene Corporation
      2021   Phase 2   EUCTR2019-004108-37-DE   Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CDP870   
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
CIMZIA certolizumab pegol 200 mg/ml solution for injection   
   UCB BIOSCIENCES GmbH
      2016   Phase 3   EUCTR2015-001894-41-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
      2015   Phase 3   EUCTR2015-001894-41-HU   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
      2015   Phase 3   EUCTR2015-001894-41-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
CNTO 148   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom;
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
CP-690,550   
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-DE   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-BG   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-AT   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10   
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
CT-P13   
   Pfizer
      2015   -   NCT02605642   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CTLA4Ig   
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany;
Cannabidiol tablet   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Cannabis   
   University Hospital, Clermont-Ferrand
      2020   -   NCT04402554   France;
Celebrex   
   Charite Universitaetsmedizin
      2016   Phase 4   EUCTR2016-000615-33-DE   Germany;
Celecoxib   
   Affiliated Hospital of Nanjing University of Chinese Medicine
      2021   Phase 0   ChiCTR2100044284   China;
   Charite University, Berlin, Germany
      2016   Phase 4   NCT02758782   Germany;
   Columbia University
      2018   Phase 4   NCT03473665   United States;
   Guangdong Provincial Hospital of Chinese Medicine
      2021   Phase 0   ChiCTR2100042789   China;
      2007   Phase 1 study   ChiCTR-TRC-13004564   China;
   Jiangsu Province Hospital of TCM
      2019   -   ChiCTR2000034142   China;
   Pfizer
      2003   Phase 3   NCT00648141   Germany;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 3   NCT00762463   China;
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Celecoxib 200 milligrams   
   Pfizer
      2002   Phase 4   NCT02528201   Norway;
Celecoxib 400 milligrams   
   Pfizer
      2002   Phase 4   NCT02528201   Norway;
Celecoxib, Celebrex®   
   Sun Yat-sen University
      2012   -   NCT01709656   China;
Certolizumab   
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
Certolizumab pegol   
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03215277   Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Certolizumab pegol (CZP)   
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Certolizumab pegol / CIMZIA   
   UCB Biosciences Inc.
      2014   Phase 1   EUCTR2013-003812-30-NL   France;Germany;Netherlands;Switzerland;United States;
Cimzia   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
Cimzia 200 mg solution for injection   
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Cimzia®   
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Conventional therapy users for the last 5 years   
   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
      2019   -   NCT04943237   Turkey;
Cosentyx   
    Rigshospitalet - Glostrup
   Afdeling for Rygkirurgi, Led- og Bindevævssygdomme
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
      -   Phase 4   EUCTR2020-004284-98-CZ   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
DMARDs   
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China;
Diclofenac   
   Chinese PLA General Hospital
      2010   Phase 1 study   ChiCTR-ONRC-10000858   China;
   Columbia University
      2018   Phase 4   NCT03473665   United States;
   Johnson & Johnson Taiwan Ltd
      2008   Phase 4   NCT00766402   -
   Pfizer
      2003   Phase 3   NCT00648141   Germany;
Diclofenac 50 milligrams   
   Pfizer
      2002   Phase 4   NCT02528201   Norway;
Diclofenac SR   
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 3   NCT00762463   China;
Diclophenac   
   Charite University, Berlin, Germany
      2008   Phase 4   NCT00715091   Germany;
Dronabinol capsule   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Drug treatment   
   University of Zurich
      2004   Phase 2   NCT01038011   Switzerland;
E-Device   
   UCB Biopharma S.P.R.L.
      2017   Phase 3   NCT03357471   United States;
ENIA11   
   Mycenax Biotech Inc.
      2016   Phase 3   NCT02685904   Taiwan;
Enbrel   
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Pfizer
      2011   -   NCT01411215   China;
      2009   -   NCT01421303   Belgium;
      2008   -   NCT01188655   -
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   WYETH LEDERLE
      2009   -   EUCTR2007-003096-39-IT   Italy;
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Wyeth Farma S.A.
      2006   -   EUCTR2006-002349-35-ES   Spain;
   Wyeth Pharmaceuticals B.V.
      2009   -   EUCTR2009-015515-40-NL   Netherlands;
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-002748-27-HU   France;Germany;Hungary;Netherlands;
      2007   -   EUCTR2006-002748-27-NL   France;Germany;Hungary;Netherlands;
      2007   -   EUCTR2006-002748-27-DE   France;Germany;Hungary;Netherlands;
      2006   Phase 4   EUCTR2006-002748-27-FR   France;Germany;Hungary;Netherlands;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Enbrel (Etanercept)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2004   Phase 4   NCT00444340   -
Enbrel (etanercept)   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 3   NCT00434044   -
      2006   Phase 4   NCT00410046   Denmark;Finland;Sweden;United Kingdom;
      2002   Phase 3   NCT00421915   -
Enbrel plus Celebrex   
   Sun Yat-sen University
      2014   Phase 4   NCT01934933   China;
Enbrel®   
   Norfolk & Norwich University Hospitals NHS Foundation Trust
      2010   Phase 4   EUCTR2010-020913-10-GB   United Kingdom;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir   
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of;
Etanercept   
   Amgen
      2002   Phase 3   NCT00356356   United States;
   AryoGen Pharmed Co.
      2014   -   NCT04582084   Iran, Islamic Republic of;
   Charite University, Berlin, Germany
      2002   Phase 2   NCT01289743   Germany;
   Chung Shan Medical University
      2008   Phase 4   NCT02489760   Taiwan;
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Nanfang Hospital of Southern Medical University
      2019   -   ChiCTR1900025749   China;
   Norfolk & Norwich University Hospitals NHS Foundation Trust
      2010   Phase 4   EUCTR2010-020913-10-GB   United Kingdom;
   Pfizer
      2020   -   NCT04507763   Iraq;
      2014   -   NCT02202850   Belgium;
      2009   Phase 4   NCT00910273   Italy;
      2007   -   NCT00544557   Germany;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2016   Phase 2/Phase 3   NCT02809781   China;
   Sun Yat-sen University
      2007   Phase 4   NCT02915354   China;
   WYETH LEDERLE
      2009   -   EUCTR2007-003096-39-IT   Italy;
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Wyeth Farma S.A.
      2006   -   EUCTR2006-002349-35-ES   Spain;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2006   Phase 4   NCT00873730   -
      2006   Phase 4   NCT00458185   -
      2005   Phase 4   NCT00247962   Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
      2005   -   NCT00195416   Korea, Republic of;
      2004   Phase 3   NCT00418548   -
      2002   Phase 3   NCT00421980   Belgium;
Etanercept (50mg per week)   
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
Etanercept (50mg per week, for 2 weeks)   
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
Etanercept (50mg per week, for 4 weeks)   
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
Etanercept (Enbrel)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00420238   France;Germany;Hungary;Netherlands;
Etanercept (Full-Dose)   
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Etanercept (Half-Dose)   
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Etanercept and its biosimilars   
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Etoricoxib   
   Organon and Co
      2011   -   NCT01327638   -
      2009   -   NCT01077843   -
      2006   -   NCT01685424   United States;
   Spanish Foundation of Rheumatology
      2010   Phase 3   NCT01091675   Spain;
Eupatilin   
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Faecal microbiota transplantation   
   Torkell Ellingsen
      2022   Phase 2   NCT04924270   -
Fengshigutong Capsule plus Imrecoxib   
   Sun Yat-sen University
      2016   Phase 4   NCT03932006   China;
Filgotinib   
   Galapagos NV
      2019   Phase 2   NCT03926195   Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
      2017   Phase 2   NCT03117270   Belgium;Bulgaria;Czechia;Estonia;Poland;Spain;Ukraine;
   Gilead Sciences
      2020   Phase 3   NCT04483700   -
      2020   Phase 3   NCT04483687   -
Focetria (Monovalent MF59-Adjuvanted vaccine)   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
GLPG0634   
   Galapagos NV
      2019   Phase 2   EUCTR2018-003933-14-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-EE   Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BE   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-003636-21-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-003636-21-EE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-003636-21-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-003636-21-BG   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-003636-21-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
GP2017   
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
GP2017 (adalimumab biosimilar)   
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-JapicCTI-184106   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
   Novartis Pharmaceuticals
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
Ginger   
   Affiliated Hospital of Nanjing University of Chinese Medicine
      2021   Phase 0   ChiCTR2100044284   China;
Gold   
   Dalian Blood Center
      2018   -   ChiCTR-DDD-17014196   China;
Golimumab   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom;
   Centocor, Inc.
      2010   Phase 3   NCT01248793   China;
   Charite University, Berlin, Germany
      2016   Phase 4   NCT02758782   Germany;
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02186873   Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
   Johnson & Johnson Private Limited
      2019   Phase 4   NCT03733925   India;
   Merck Sharp & Dohme Corp.
      2012   Phase 4   NCT01668004   Netherlands;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
Golimumab (CNTO 148)   
   Centocor, Inc.
      2005   Phase 3   NCT00265083   Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom;United States;
Golimumab Injection   
   MSD Pharmaceuticals LLC
      2016   -   NCT03557853   Russian Federation;
Golimumab Liquid in Vial   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
Golimumab Pre-Filled Syringe   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
Herpes Zoster Vaccine   
   University of Alabama at Birmingham
      2016   Phase 2   NCT02538341   United States;
      2013   Phase 2   NCT02538757   United States;
Human Anti-TNF IgG1 Monoclonal Antibody   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom;
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
Human Anti-TNFalfa   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom;
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
Human anti-TNFa monoclonal antibody   
   Janssen Biologics, BV
      2014   Phase 3   EUCTR2014-000241-74-DE   Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
Human umbilical cord-derived MSCs   
   Shandong University
      2011   Phase 1   NCT01420432   China;
Humira   
   Abbott GmbH & Co. KG
      2007   -   EUCTR2005-004826-21-BE   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004826-21-DK   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-SE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-IE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-GR   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-GB   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-FI   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-ES   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-DE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004826-21-AT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
   Abbott Laboratories
      2006   -   EUCTR2005-004826-21-NO   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
   Bio-Thera Solutions
      2016   Phase 3   NCT04135508   -
   Clinical Immunology and Rheumatology
      2009   -   EUCTR2008-006885-27-NL   Netherlands;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Faculdade de Ciências Médicas da Universidade Nova de Lisboa
      2014   Phase 4   EUCTR2013-004406-25-PT   Portugal;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Regionalhospital Silkeborg
      2010   Phase 4   EUCTR2009-018085-35-DK   Denmark;
Humira 40 mg/0.8 ml solution for injection   
   Abbott
      -   -   EUCTR2014-004532-18-Outside-EU/EEA   Japan;
Humira®   
   Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
      2008   -   EUCTR2007-003358-27-DE   Germany;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine   
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
Hyrimoz   
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
IBI303   
   Innovent Biologics (Suzhou) Co. Ltd.
      2016   Phase 3   NCT02893254   -
Ibuprofen   
   School of Chinese Medicine Southern Medical University
      2010   -   ChiCTR-TRC-11001274   China;
Iguratimod   
   PLA General Hospital
      2018   -   ChiCTR1800019227   China;
   Qilu Hospital of Shandong University
      2021   Phase 4   ChiCTR2100043171   China;
Ilumetri   
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Indomethacin   
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
   Columbia University
      2018   Phase 4   NCT03473665   United States;
   Sun Yat-sen Memorial Hospital of Sun Yat-sen University
      2011   Phase 1+Phase 2   ChiCTR-TRC-11001417   China;
Infliximab   
   Association de Recherche Clinique en Rhumatologie
      2003   Phase 3   NCT00439283   France;
   Celltrion
      2012   Phase 1   NCT01571206   Korea, Republic of;
      2010   Phase 1   NCT01220518   Korea, Republic of;
   Centocor, Inc.
      2002   Phase 3   NCT00207701   -
   Chiba University Hospital
      2012   Phase 2   JPRN-UMIN000015297   Japan;
      2012   Phase 2   JPRN-UMIN000007806   Japan;
   Gu Jieruo
      2008   Phase 4   NCT00936143   China;
   Göteborg University
      2003   -   NCT01850121   Sweden;
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
      2007   -   NCT00724529   Korea, Republic of;
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China;
   Merck Sharp & Dohme Corp.
      2010   Phase 4   NCT01148901   Spain;
      2009   Phase 3   NCT00844805   Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
      2005   Phase 3   NCT00202865   Canada;
      2004   Phase 4   NCT00779012   -
      2004   -   NCT00725543   -
      2003   -   NCT00818168   Germany;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Rheumazentrum Ruhrgebiet
      2005   -   NCT00237419   Belgium;Finland;France;Germany;Netherlands;United Kingdom;
   Rheumazentrum Ruhrgebiet.
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom;
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom;
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom;
   Schering-Plough France
      2008   -   EUCTR2006-001579-40-DK   Denmark;France;Hungary;Spain;
      2007   Phase 4   EUCTR2006-001579-40-HU   Denmark;France;Hungary;Spain;
      2007   Phase 4   EUCTR2006-001579-40-FR   Denmark;France;Hungary;Spain;
      2007   -   EUCTR2006-001579-40-ES   Denmark;France;Hungary;Spain;
   University Hospital, Tours
      2007   Phase 4   NCT00507403   France;
Infliximab (BCD-055)   
   Biocad
      2015   Phase 1   NCT02359903   Belarus;Russian Federation;
Infliximab (Remicade)   
   Biocad
      2015   Phase 1   NCT02359903   Belarus;Russian Federation;
Infliximab and MTX   
   Chinese University of Hong Kong
      2005   Phase 4   NCT00432432   -
Infliximab biosimilar   
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Intravenous infusion of MSCs   
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2016   Phase 2/Phase 3   NCT02809781   China;
Ixekizumab   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly & Company
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
      2014   Phase 3   NCT01870284   Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
JS005   
   Shanghai Junshi Bioscience Co., Ltd.
      2021   Phase 2   NCT05212051   China;
Jaktinib Hydrochloride Tablets   
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2020   Phase 2   NCT04507659   -
Jing Si Herbal Tea LIQUID PACKETS   
   Buddhist Tzu Chi General Hospital
      2022   -   NCT05257174   Taiwan;
KIN-1901   
   Kinevant Sciences GmbH
      2019   Phase 1   NCT04205851   Canada;
Kunxian capsule   
   Gu Jieruo
      2008   Phase 4   NCT00953979   China;
L04AA24   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AB01   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AB04   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AB05   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
LSD   
   Universidade do Porto
      2020   -   NCT04386538   Portugal;
LY2439821   
   Eli Lilly & Company
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Leflunomide   
   The First Affiliated Hospital of Heilongjiang Chinese Medicine Colledge
      2018   -   ChiCTR-INR-17013574   China;
Loxoprofen sodium hydrogel patch   
   Sun Yat-sen University
      2015   Phase 4   NCT03800797   China;
Loxoprofen sodium tablet   
   Sun Yat-sen University
      2015   Phase 4   NCT03800797   China;
Lyophilized etanercept powder(Yisaipu)   
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2014   Phase 3   NCT04345458   China;
METHOTREXATE DISODIUM   
   CHRU de TOURS
      2013   Phase 4   EUCTR2012-004939-23-FR   France;
METOJECT   
   CHRU de TOURS
      2013   Phase 4   EUCTR2012-004939-23-FR   France;
MK-0663   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019872-65-GB   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
MK-3222   
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
MRNA COVD19 vaccine   
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States;
MSB11022   
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States;
MSC   
   Sun Yat-sen University
      2012   -   NCT01709656   China;
MTX   
   Department of rheumatology of the Chinese PLA General Hospital
      2015   -   ChiCTR-IPR-15006753   China;
MabThera 500   
   University Hospital of North Staffordshire
      2006   Phase 2   EUCTR2005-005358-27-GB   United Kingdom;
Meloxicam   
   Columbia University
      2018   Phase 4   NCT03473665   United States;
   Shanghai University of Traditional Chinese Medicine
      2017   Phase 2/Phase 3   NCT04480359   China;
Meloxicam suppository   
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
Meloxicam tablet   
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
Methotrexate   
   Association de Recherche Clinique en Rhumatologie
      2003   Phase 3   NCT00439283   France;
   Charite University, Berlin, Germany
      2003   Phase 2   NCT00243750   Germany;
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
   Merck Sharp & Dohme Corp.
      2010   -   NCT01313858   Germany;
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
   University Hospital, Tours
      2013   Phase 4   NCT01895764   France;
Methylprednisolone   
   Saratov State Medical University
      2012   Phase 2   NCT01790022   Russian Federation;
Misoprostol   
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of;
Monoclonal Antibody (MAb)   
   Eli Lilly & Company
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Méthotrexate Bellon Comprimé   
   CHRU-TOURS
      2007   -   EUCTR2006-005157-29-FR   France;
N.A.   
   Boehringer Ingelheim
      2014   Phase 2   EUCTR2013-003666-13-IT   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
NSAIDs   
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China;
   University Hospital, Bordeaux
      2015   Phase 3   NCT02469753   France;Monaco;
NSAIDs and sulfasalazine   
   Chung Shan Medical University
      2009   Phase 2   NCT02456363   Taiwan;
Nanocurcumin   
   Tabriz University of Medical Sciences
      2017   Phase 2   NCT03140657   Iran, Islamic Republic of;
Naprosyn   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019872-65-GB   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naprosysn   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019872-65-GB   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naproxen   
   Merck Sharp & Dohme Corp.
      2009   Phase 3   NCT00844805   Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
Naproxen 500 mg tablets (PN 200 minus omeprazole)   
   POZEN
      2006   Phase 3   NCT00367211   United States;
Non-anti-TNF biologics   
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
None   
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2009   -   ChiCTR-ONRC-11001565   -
Normal saline   
   Inmagene Biopharmaceuticals
      2021   Phase 2   NCT04795141   Cayman Islands;
NsNSAIDs   
   Organon and Co
      2011   -   NCT01327638   -
Observational study   
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
Olsalazine   
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004288   -
Oral   
   Pfizer
      2008   Phase 2   NCT00811499   Canada;United States;
Orencia   
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
Originator   
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia;
Originator (legacy) drug   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
Other COX-2 inhibitor   
   Organon and Co
      2011   -   NCT01327638   -
Other Cox-2 inhibitors   
   Organon and Co
      2009   -   NCT01077843   -
Other Non-selective NSAIDs   
   Organon and Co
      2009   -   NCT01077843   -
Oxygen   
   Shenzhen Second People's Hospital
      2021   -   ChiCTR2100042477   China;
PN 200 tablets (500 mg naproxen and 20 mg omeprazole)   
   POZEN
      2006   Phase 3   NCT00367211   United States;
Pamidronate   
   Bnai Zion Medical Center
      2014   Phase 4   NCT02313727   Israel;
Parecoxib   
   Peking Union Medical College Hospital
      2014   -   ChiCTR1800014846   China;
Part I - etoricoxib   
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part I- naproxen   
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- etoricoxib   
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- naproxen   
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Placebo   
   UCB Japan Co., Ltd
      2019   Phase 3   JPRN-JapicCTI-194860   Japan, Asia except Japan, North America;
Prednisolone   
   Charite University, Berlin, Germany
      2002   Phase 2/Phase 3   NCT00244166   Germany;
Prefilled liquid etanercept(Yisaipu)   
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2014   Phase 3   NCT04345458   China;
REMICADE 100 mg polvo para concentrado para solución para perfusión   
   Schering Plough, S.A
      2010   -   EUCTR2009-016587-36-ES   Spain;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión   
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-017488-40-ES   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RTNV148B IgG   
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom;
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom;
Rebamipide   
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of;
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Recombinant TNF-a receptor: IgG Fc fusion protein   
   Zhejiang Hisun Pharmaceutical Co. Ltd.
      2018   -   NCT03636984   -
Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class   
   Novartis Pharma Services AG
      2010   Phase 2   EUCTR2009-011591-30-GB   Germany;Netherlands;United Kingdom;
      2010   -   EUCTR2009-011591-30-NL   Germany;Netherlands;United Kingdom;United States;
      2010   -   EUCTR2009-011591-30-DE   Germany;Netherlands;United Kingdom;
      2009   -   EUCTR2008-002631-33-NL   Germany;Netherlands;United Kingdom;
      2009   -   EUCTR2008-002631-33-GB   Germany;Netherlands;United Kingdom;
      2008   -   EUCTR2008-002631-33-DE   Germany;Netherlands;United Kingdom;
Remicade   
   Merck Sharp & Dohme Corp.
      2005   Phase 4   NCT00778869   -
      2004   Phase 4   NCT00779935   -
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Rheumazentrum Ruhrgebiet.
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom;
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom;
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom;
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom;
   Schering-Plough France
      2008   -   EUCTR2006-001579-40-DK   Denmark;France;Hungary;Spain;
      2007   Phase 4   EUCTR2006-001579-40-HU   Denmark;France;Hungary;Spain;
      2007   Phase 4   EUCTR2006-001579-40-FR   Denmark;France;Hungary;Spain;
      2007   -   EUCTR2006-001579-40-ES   Denmark;France;Hungary;Spain;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
Remicade®   
   Biocad
      2016   Phase 3   NCT02762812   Russian Federation;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
RhuTNFR:Fc   
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Rinvoq   
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2019-003229-12-SK   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab   
   AbbVie
      2014   Phase 2   NCT02047110   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Rituximab   
   Charite University, Berlin, Germany
      2007   Phase 2/Phase 3   NCT00432653   Germany;
Rituximab/ Mabthera   
   Charité Universitaetsmedizin
      2006   -   EUCTR2006-002306-64-DE   Germany;
Ro 487-533/F01   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2009-017488-40-BE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-017488-40-GB   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-SK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-DK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-DE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-BG   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-5733/F01   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 2;Phase 3   EUCTR2009-017443-34-BE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2009-017443-34-DE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
      2011   -   EUCTR2009-017443-34-BG   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   Phase 2;Phase 3   EUCTR2009-017443-34-GB   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-SK   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-CZ   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-7533/F01   
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro45-2294   
   Charité Universitaetsmedizin
      2006   -   EUCTR2006-002306-64-DE   Germany;
RoActemra   
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-017488-40-IT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-IT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RoActemra®   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2009-017488-40-BE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2009-017443-34-BE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2009-017443-34-DE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
      2011   -   EUCTR2009-017443-34-BG   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-017488-40-GB   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   Phase 2;Phase 3   EUCTR2009-017443-34-GB   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-SK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-DK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-DE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-BG   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-SK   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-CZ   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Rosuvastatin   
   Diakonhjemmet Hospital
      2013   -   NCT01389388   Norway;
SAR153191   
   Sanofi-aventis Recherche & Développement
      2010   Phase 2   EUCTR2009-016068-35-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   Phase 2   EUCTR2009-016068-35-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
      2010   -   EUCTR2009-016068-35-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
   sanofi-aventis Recherche & Développement
      2010   Phase 3   EUCTR2010-019263-11-FR   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   Phase 3   EUCTR2010-019263-11-ES   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   Phase 3   EUCTR2010-019263-11-BE   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   -   EUCTR2010-019263-11-LT   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   -   EUCTR2010-019263-11-HU   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   -   EUCTR2010-019263-11-CZ   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
      2010   -   EUCTR2010-019263-11-AT   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
SB4 (etanercept biosimilar)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5   
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SHR-1314   
   Suzhou Suncadia Biopharmaceuticals Co., Ltd.
      2021   Phase 2/Phase 3   NCT04840485   China;
SHR0302   
   Jiangsu HengRui Medicine Co., Ltd.
      2020   Phase 2/Phase 3   NCT04481139   China;
SUNPG1622 I dose   
   Sun Pharmaceutical Industries Limited
      2017   Phase 2   NCT02980705   Hungary;Poland;Spain;United States;
Salicylazosulfapyridine   
   Sun Yat-sen Memorial Hospital of Sun Yat-sen University
      2011   Phase 1+Phase 2   ChiCTR-TRC-11001417   China;
Sarilumab   
   Sanofi
      2010   Phase 2   NCT01118728   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Lithuania;Netherlands;Poland;Spain;United States;
      2010   Phase 2   NCT01061723   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Netherlands;Poland;Spain;Turkey;United States;
Secukinumab   
   NOVARTIS FARMA
      2011   -   EUCTR2010-024529-18-IT   Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
   Novartis Farma SpA
      2013   Phase 3   EUCTR2013-001089-40-IT   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-JapicCTI-184106   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024529-18-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      2022   -   NCT05155098   -
      2019   Phase 3   NCT04156620   Belgium;Brazil;Bulgaria;Colombia;Czechia;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   NCT02896127   China;Czech Republic;Czechia;Korea, Republic of;United Kingdom;
      2015   Phase 3   NCT02159053   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2014   Phase 3   NCT02008916   Belgium;Czech Republic;Czechia;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   NCT01863732   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (150 mg)   
   Novartis Pharmaceuticals
      2012   Phase 3   NCT01649375   Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2011   Phase 3   NCT01358175   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (75 mg)   
   Novartis Pharmaceuticals
      2012   Phase 3   NCT01649375   Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
      2011   Phase 3   NCT01358175   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (AIN457) 150 mg s.c.   
   Novartis Pharmaceuticals
      2016   Phase 4   NCT02763046   Germany;
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.   
   Novartis Pharmaceuticals
      2016   Phase 3   NCT02750592   Japan;
Secukinumab 150 mg/1 ml Solution for injection   
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab 150 milligram [Cosentyx]   
   Professor Mikkel Østergaard
      2019   Phase 4   NCT03639740   Denmark;
Secukinumab 75 mg/0.5 ml Solution for injection   
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Simponi   
   Charite Universitaetsmedizin
      2016   Phase 4   EUCTR2016-000615-33-DE   Germany;
   Chinese University of Hong Kong
      2010   Phase 4   NCT01212653   China;
   MERCK SHARP & DOHME B.V.
      2012   Phase 4   EUCTR2012-002458-21-NL   Netherlands;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
Simponi®   
   Merck Sharp & Dohme Corp.
      2010   -   NCT01313858   Germany;
Sodium chloride   
   Chinese University of Hong Kong
      2010   Phase 4   NCT01212653   China;
Stelara   
   Charité Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-000844-56-DE   Germany;
Sulfasalazine   
   Nanchang Hongdu Hospital of TCM
      2020   -   ChiCTR2000038277   China;
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China;
   School of Chinese Medicine Southern Medical University
      2010   -   ChiCTR-TRC-11001274   China;
   Sun Yat-sen University
      2008   Phase 2/Phase 3   NCT00889694   -
   WYETH LEDERLE
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Sulfasalazine, SSZ   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Sulphasalazine (SSZ)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 4   NCT00247962   Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
Sulphasalazine 500 mg En-Tabs   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Systemic non-biological treatments   
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
TA-650 (Infliximab)   
   Mitsubishi Tanabe Pharma Corporation
      -   Phase 3   JPRN-JapicCTI-070346   -
THA   
   99 Huaihai Road West, Xuzhou, Jiangsu, China
      2019   -   ChiCTR1900025635   China;
TNF alpha   
   Chung Shan Medical University
      2009   Phase 2   NCT02456363   Taiwan;
TNF blockers (infliximab, adalimumab, etanercept)   
   University of Sao Paulo
      2008   Phase 4   NCT01072058   Brazil;
TNF-a antagonists, non-TNFs, DMARD non-biologics   
   Biologics & Biosimilars Collective Intelligence Consortium
      2012   -   NCT02922192   -
TNF-alpha antagonists   
   Assistance Publique - Hôpitaux de Paris
      2004   -   NCT00224562   France;
TNF-inhibition   
   Region Skane
      2019   -   NCT03839862   Sweden;
TNFR:Fc   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001   
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom;
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001, TNFR:FC   
   Wyeth Farma S.A.
      2006   -   EUCTR2006-002349-35-ES   Spain;
TOFACITINIB CITRATE   
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-DE   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-BG   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-AT   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Taltz (80 mg solution for injection in pre-filled syringe)   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tapering or discontinuation of etanercept   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2012   -   NCT03880968   -
Technetium labelled glucosamine   
   University of Sydney
      2012   -   NCT01789151   Australia;
Terbinafine Tablets   
   Oregon Health and Science University
      2021   Early Phase 1   NCT05119712   United States;
Thalidomide   
   Chinese PLA General Hospital
      2010   Phase 1 study   ChiCTR-ONRC-10000858   China;
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2009   -   ChiCTR-ONRC-11001846   -
   Shanghai Pharmaceuticals Holding Co., Ltd
      2013   Phase 2   NCT02201043   China;
   The General Hospital of People's Liberation Army
      2013   Phase 2 study   ChiCTR-TRC-13003449   China;
Tildrakizumab   
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Tildrakizumab 100 mg/ml   
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Tocilizumab   
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017488-40-IT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
   Hoffmann-La Roche
      2010   Phase 3   NCT01209702   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;India;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   NCT01209689   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;India;Italy;Lithuania;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
Tofacitinib   
   Pfizer
      2018   Phase 3   NCT03502616   Australia;Bulgaria;Canada;China;Czechia;France;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
      2013   Phase 2   NCT01786668   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
Tofacitinib XR   
   Pfizer
      2021   -   NCT04876781   -
Total Glucosides Paeony Capsules   
   Sun Yat-sen University
      2011   Phase 4   NCT01517620   China;
Tramadol /acetaminophen   
   Johnson & Johnson Taiwan Ltd
      2008   Phase 4   NCT00766402   -
Tripterygium   
   Sun Yat-sen University
      2008   Phase 2/Phase 3   NCT00889694   -
Tripterygium Wilfordii   
   Jiangsu Provincial Hospital of Traditional Chinese Medicine
      2011   -   ChiCTR-TRC-11001193   China;
UCB4940   
   UCB BIOPHARMA SRL
      2018   Phase 2   EUCTR2017-001002-15-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
   UCB BIOSCIENCES GmbH
      2017   Phase 2   EUCTR2017-001002-15-HU   Hungary;
   UCB Biopharma SPRL
      2019   Phase 3   EUCTR2017-003065-95-FR   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-ES   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-001002-15-ES   Germany;Hungary;Spain;
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
      2017   Phase 2   EUCTR2016-001102-42-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001102-42-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2016-001102-42-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001102-42-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001102-42-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001102-42-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   UCB Biopharma SRL
      2020   Phase 3   EUCTR2019-004163-47-HU   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004163-47-GB   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004163-47-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004163-47-CZ   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004163-47-BG   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-NL   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-HU   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-GB   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-BG   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-003065-95-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001002-15-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 2   EUCTR2017-001002-15-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
   UCB Japan Co., Ltd
      2019   Phase 3   JPRN-JapicCTI-194860   Japan, Asia except Japan, North America;
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205414   Japan, Asia except Japan, North America, Europe;
Ultracet   
   Chung Shan Medical University
      2008   Phase 4   NCT00647517   Taiwan;
Upadacitinib   
   AbbVie
      2021   -   NCT05094128   Germany;
      2017   Phase 2   NCT03178487   Australia;Belgium;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-SE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-NL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-HR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-DE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-HU   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-GB   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FI   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-ES   Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-DK   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-CZ   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-BE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ustekinumab   
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01330901   Germany;
   Charité Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-000844-56-DE   Germany;
Vessel   
   Guangdong Provincial Hospital of Chinese Medicine
      2007   Phase 1 study   ChiCTR-TRC-13004564   China;
Voltaren resinat   
   Charité - Campus Mitte
      2008   Phase 4   EUCTR2007-007637-39-DE   Germany;
Xeljanz   
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Yisaipu®   
   Nanfang Hospital of Southern Medical University
      2017   Phase 4   NCT03411798   China;
Yuxuebi tablet   
   China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
      2021   Phase 4   NCT04934059   China;
double-blinded secukinumab   
   Novartis Pharmaceuticals
      2018   Phase 4   NCT03350815   United States;
open-label secukinumab   
   Novartis Pharmaceuticals
      2018   Phase 4   NCT03350815   United States;